🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07365553
Recruiting Not applicable

Omega-3, Autism Spectrum Disorder (ASD)

NCT07365553 · tracked via the Priya Life Science China tracker
Sponsor
China Medical University Hospital
Phase
Not applicable
Started
2022-07-15
Last updated
2026-01-26

Condition(s) studied

ASD

Investigational drug(s) / intervention(s)

Omega-3Placebo

Omega-3: Omega-3 PUFAs

Placebo: Soybean Oil

Study summary

This is a 12 week study to investigate the effects of omega-3 polyunsaturated fatty acids (PUFAs) in youth with autism spectrum disorder (ASD).

Eligibility

Sex
ALL
Min age
6 Years
Max age
17 Years
Healthy volunteers
No
Inclusion Criteria: * diagnosis of DSM5 ASD made by child and adolescent psychiatrist * age 6-17 years-old at the time of enrolment * no pharmacotherapy or non-pharmacotherapy adjustment within the past 4 weeks, * Signed informed consent. Exclusion Criteria: * comorbid other psychiatric disorders, including schizophrenia or affective mood disorder (Bipolar and Major Depressive Disorder), or substance use disorder * comorbid physical disorders, such as thyroid dysfunction, cerebral palsy, coagulation disorders * currently using omega-3 supplements or probiotics * allergy to omega-3.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
China Medical University Taichung Taichung Recruiting

More China Medical University Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07365553 on ClinicalTrials.gov ↗ ← All trials in China